oncology gradeSintaho Pharmaceutical Ltd was established in the year of 2016 and headquartered in Chongqing China, with a grand vison of being the most trusted partner to pharmaceutical companies worldwide. We have a clear focus on developing and manufacturing highly potent and cytotoxic Active Pharmaceutical Ingredients (APIs) and CDMO services.
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p><strong>Encequidar Methanesulfonate Monohydrate</strong> is a specialized pharmaceutical intermediate primarily utilized in oncology research. Synthesized via controlled crystallization of the parent compound with methanesulfonic acid, it enhances solubility and stability for formulation. The chemical structure is defined by the molecular formula C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>6</sub>S·H<sub>2</sub>O and registered under CAS No. 2097658-59-8.</p>
<h3>Application</h3>
<ul>
<li>Development of P-glycoprotein inhibitors to reverse multidrug resistance in cancer cells.</li>
<li>Preclinical pharmacokinetic studies focusing on blood-brain barrier penetration.</li>
<li>Manufacturing of targeted therapeutic agents for refractory solid tumors.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly for R&D use only; not approved for clinical administration. Store under inert atmosphere at 2-8°C to prevent hydration loss. Handle with appropriate PPE due to potential toxicity and sensitization risks during processing.</p>